Standout Papers
- Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial (2019)
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus (2019)
- Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials (2023)
Citation Impact
3 from Science/Nature 55 standout
Citing Papers
Therapeutic advances in rheumatoid arthritis
2024 Standout
mRNA vaccines for infectious diseases — advances, challenges and opportunities
2024 Standout
Works of Anna Berglind being referenced
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
2023 Standout
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
2019 Standout
Author Peers
| Author | Rheumatology | Oncology | RNMI | Immunology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Anna Berglind | 931 | 214 | 401 | 721 | 12 | 1.3k | |
| Akihiro Hino | 1 | 30 | 52 | 44 | 16 | 384 | |
| Ikram A. Tirmizi | 20 | 375 | |||||
| Sascha Mühlenhoff | 4 | 13 | 456 | ||||
| Masanori Fujinami | 6 | 16 | 3 | 133 | 1.9k | ||
| Tim Craft | 19 | 145 |
All Works
Loading papers...